Formulation is where the Opticeutical Standard meets supply chain, manufacturing, and quality verification. Six formulation principles govern the translation.
A bottle with the right ingredient list at the wrong dose, in the wrong form, made in the wrong facility, verified by nobody, is not an Opticeutical.
The most common failure mode in the nutraceutical category is not ingredient selection. It is the gap between what the label asserts and what the capsule actually delivers. Formulation discipline closes that gap. The six principles below are how the Opticeutical Standard becomes operational rather than aspirational.
Every active ingredient is selected in the form the body can actually use. Methylfolate rather than folic acid. Methylcobalamin rather than cyanocobalamin. Magnesium glycinate or malate rather than magnesium oxide. The decision is made against published absorption and utilization data, not against ingredient cost.
Each active appears at a dose supported by the published evidence base for the intended functional outcome. The standard rejects token doses — quantities chosen to support a label claim without supporting a biological effect. A formulation either delivers a clinically relevant dose of an active or it does not include that active.
Multiple actives in a single formulation must have a coherent mechanism rationale for being combined. Synergies are documented. Antagonisms are excluded. Combination is not justified by category convention or by competitive parity — it is justified by mechanism.
Inactive ingredients — binders, fillers, flow agents, capsule materials — are selected against the same standard as the actives. Synthetic dyes, hydrogenated oils, and unnecessary fillers are excluded. Excipients exist to deliver the active, not to add cost margin or volume.
Production occurs in cGMP-certified facilities with documented batch records, environmental controls, and process validation. Change control is enforced. Material flow is traceable. The manufacturing facility is treated as part of the product, not as a vendor relationship to be optimized for price.
Every production batch is verified by an ISO 17025 accredited third-party laboratory for identity, potency, and contaminant load. Certificates of analysis are retained and made available. Verification is per-batch, not per-product-line, because variation in raw material lots is the actual failure mode.
The Opticeutical Standard does not invent new manufacturing or verification frameworks. It references the standards already in wide use across pharmaceutical, food, and supplement industries and requires their consistent application.
The FDA Current Good Manufacturing Practice regulations specific to dietary supplements. Governs facility, process, personnel, equipment, and quality-control requirements. Anchors the Manufacturing Discipline principle.
The international standard for testing and calibration laboratory competence. Verification partners must hold ISO 17025 accreditation. Anchors the Verification at Batch Level principle.
Compendial monographs for ingredient identity, strength, purity, and quality. USP Verified Mark verification is one accepted pathway. Anchors the Composition Rigor and Verification principles.
The American National Standard for dietary supplements, administered by NSF International. Covers content verification, contaminant testing, and manufacturing audit. Another accepted verification pathway.
LGC's certification program for sports products. Tests every production batch against the WADA prohibited list. Required where the product is intended for athletes subject to anti-doping testing.
Hazard analysis and risk-based preventive controls for human food. Applicable to ingredient sourcing and supply-chain management. Anchors the Sourcing Integrity principle.
The standard accepts any equivalent international framework (e.g., EU GMP, PIC/S) where the formulation is produced for non-U.S. markets. Equivalence is determined by independent audit against the relevant U.S. anchor standard.
Delivery form is part of formulation, not separate from it. A given active — whether a vitamin, a botanical extract, or a peptide-class bioregulator — may be appropriate as a capsule, a sublingual lozenge, a transdermal preparation, or a liquid, depending on its absorption profile, stability requirements, and the functional outcome being sought. Selecting the wrong delivery form for a given active undermines the formulation regardless of how the rest of the principles are executed.
Where the active is moisture-sensitive, pH-sensitive, or subject to rapid enzymatic degradation — as is typical for short-chain peptide compounds — formulation often requires a therapeutic salt carrier. Therapeutic salts provide pharmaceutically defensible stabilization, controlled dissolution, and bioavailability tuning without the regulatory weight of a new excipient class. The Opti-Salt™ carrier family, developed for the Opticeutical category, is one example of this approach codified into a named delivery system.
The standard treats delivery form as a formulation decision subject to the same evidence orientation as ingredient selection. A capsule that bypasses the stomach acid environment when the active requires it. A sublingual when first-pass metabolism would disqualify oral delivery. A liquid where capsule disintegration timing would compromise efficacy. For the full delivery portfolio organized by route, see the platforms.